🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Juno and bluebird bio set for pullbacks after recent run-ups, both down 2% premarket

Published 09/05/2017, 09:01 AM
© Reuters.  Juno and bluebird bio set for pullbacks after recent run-ups, both down 2% premarket
BLUE
-
SB9
-
  • CAR-T developers Juno Therapeutics (NASDAQ:JUNO) and bluebird bio (NASDAQ:BLUE) are both down 2% premarket on light volume signaling possible profit-taking today after significant rallies. Juno was up almost 70% and bluebird 37%, stoked by Gilead's $11.9B takeout of Kite Pharma.
  • Cellectis' stumble with UCART123 is adding pressure as well.
  • Previously: Cellectis down 29% premarket on FDA hold on studies of UCART123 after fatality (Sept. 5)
  • Now read: Juno Therapeutics Is Not Kite Pharma; We Are Short Juno

Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.